University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 18 of 35

COMPLETED NA

Integrative Approaches for Cancer Survivorship 2: Project 2

NCT02897544

COMPLETED NA

Nuevo Amanecer II: Translating a Stress Management Program for Latinas

NCT02931552

COMPLETED Phase 3

Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

NCT02731638

COMPLETED

Ultra Dual-Energy X-ray Absorptiometry (DXA): Accurate and Precise Quantitative Multi-compartment Body Composition

NCT03430323

COMPLETED

Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer

NCT03045575

COMPLETED NA

Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care

NCT03217058

COMPLETED NA

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233

COMPLETED NA

The Moms Online Video Exercise Study

NCT02805140

COMPLETED Phase 2

N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI

NCT02791945

COMPLETED Phase 4

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

NCT02533934

COMPLETED NA

Health-E You: Reducing Unintended Pregnancies Among Hispanic Adolescents

NCT02847858

TERMINATED Phase 3

Bococizumab HIV Evaluation (B-HIVE) Study

NCT02524106

COMPLETED Phase 1

Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients

NCT02617407

TERMINATED NA

Feasibility And Efficacy Of An iPad-Based Cognitive Rehabilitation Program In Brain Tumor Patients

NCT02783495

COMPLETED NA

CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer

NCT02613273

COMPLETED NA

Single Cell Genomics of Psoriatic Skin

NCT02929745

COMPLETED NA

Paired Integrative Exercise Program for People With Dementia and Caregivers

NCT02729311

COMPLETED NA

Exercise Intervention in Liver Transplant Patients

NCT02367092

COMPLETED NA

Quality of Life in Kidney Stone Patients Undergoing Surgery

NCT02625051

COMPLETED NA

Arista for ALT Donor Sites to Reduce Drain Output

NCT02477774

COMPLETED NA

SFGH Health Advocates Stage II Study

NCT02746393

TERMINATED NA

Immobilization of Postoperative Distal Radius Fractures

NCT02802774

COMPLETED NA

Active Surveillance Exercise Clinical Trial

NCT02435472

COMPLETED

Evaluating Multivariate MRI Maps of Body Awareness

NCT03344081

COMPLETED NA

Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort

NCT02910037

COMPLETED NA

Effect of Betaine and Food on Gastric pH

NCT02758015

COMPLETED Phase 2

Ahmed Glaucoma Valve Surgery With Mitomycin-C

NCT02805257

COMPLETED Phase 1

Bevacizumab Therapy for Brain Arteriovenous Malformation

NCT02314377

COMPLETED NA

Cigarette Reduction Using the Quitbit Digital Lighter and Mobile Application for Smoking Cessation: a Randomized Controlled Trial

NCT02515500

TERMINATED NA

A Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty

NCT02634619

COMPLETED NA

CRUSH-PrEP for Women Project

NCT02852226

COMPLETED Phase 1

Assessment of 2012 Bioequivalence Standards for Warfarin

NCT02574754

COMPLETED Phase 4

The Role of Orexin in Human Panic Disorder

NCT02593682

COMPLETED Phase 4

Cryoanalgesia vs. Epidural in the Nuss Procedure

NCT02721017

COMPLETED NA

Primary Care eHealth Intervention for Improved Outcomes in Chronic Kidney Disease

NCT02097550

COMPLETED Phase 4

Programmed Intermittent Bolus Dosing Versus Continuous Epidural Infusion for Epidural Analgesia in Abdominal Surgery.

NCT03307174

COMPLETED Phase 1

A Trial of Doxycycline in Renal Disease

NCT02753426

COMPLETED Phase 2

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

NCT02684578

COMPLETED Phase 1

Effect of Clemastine Fumarate on Color Vision in Healthy Controls

NCT02613091

COMPLETED NA

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

NCT02719665

TERMINATED Phase 4

Clinical Trial of NAC in Asthma

NCT02605824

COMPLETED Phase 4

Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant

NCT02429869

COMPLETED Phase 4

Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging

NCT02807779

COMPLETED Early Phase 1

The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD

NCT02469259

COMPLETED Phase 2

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

NCT02710214

COMPLETED NA

A Mindfulness Mobile Intervention Targeting Reductions in Food Cravings

NCT02694731

COMPLETED NA

The Effect of a Novel Audit and Feedback Bundle on Inpatient Performance

NCT02593253

COMPLETED NA

Study of Refeeding to Optimize iNpatient Gains

NCT02488109

COMPLETED Phase 4

Treatment of Incontinence Without Memory Problems

NCT02436889

COMPLETED NA

Effect of Location of Tetanic Stimuli on Photoplethysmogram Under General Anesthesia

NCT05899686

← Previous Page 18 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.